Kastair

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Kastair

Quick Facts

Property Description
Active ingredient Montelukast sodium
Form Oral tablet, chewable tablet, oral granules
Pharmacological class Leukotriene Receptor Antagonist (LTRA)
Common use Long-term control and maintenance therapy
Origin Synthetic compound
Rx Status Prescription Drug (Rx)

What Type of Medicine is Kastair and What is its Composition?

Kastair is a brand-name prescription-only medication that belongs to the Leukotriene Receptor Antagonist (LTRA) pharmacological class. The medicine is a single-ingredient product, containing the active substance, Montelukast sodium (INN), which is a synthetic compound.

The primary route of administration for this drug is oral, with the active ingredient formulated into several distinct dosage forms, notably the standard oral tablet, the film-coated tablet, and the chewable tablet, which is often designed to enhance administration, particularly for pediatric patients. This specific LTRA formulation is recognized for its high specificity in blocking the cysteinyl leukotriene receptor.

How Does a Leukotriene Receptor Antagonist Generally Help?

The general therapeutic purpose of Kastair is to facilitate long-term maintenance by managing chronic airway inflammation through the targeted blocking of inflammatory messengers called leukotrienes (such as LTD4). These mediators are naturally released in the body and are known to contribute to tissue swelling and muscle tightening in the respiratory system.

By interrupting this specific inflammatory pathway, the medicine helps to prevent the cycle of events that results in progressive airway narrowing. Montelukast is a compound used to antagonize the effects of leukotrienes in the airway. This action ensures the drug is utilized as a regular, preventative component of therapy. The resulting general benefit is sustained assistance in maintaining open, relaxed airways, thereby reducing the underlying physiological burden of chronic inflammation.

What side effects are possible with Kastair?

Possible Side Effects and Safety Information

Kastair (Montelukast) is associated with officially documented side effects and regulatory warnings, which classify its known risks.

Serious and Clinically Significant Adverse Reactions

The most significant safety alert concerns neuropsychiatric events, which have been reported in all age groups. These serious side effects can include changes in mood and behavior such as agitation, aggression, anxiety, depression, dream abnormalities, hallucinations, and, rarely, suicidal thoughts and actions. The US Food and Drug Administration (FDA) requires a Boxed Warning to highlight this risk. These symptoms have been reported during treatment, and in some cases, they persisted after the medication was stopped.

Another very rare but serious condition reported is systemic eosinophilia which can present with features of vasculitis consistent with Churg-Strauss Syndrome (CSS).

Adverse Reaction Frequency

Side effects are categorized by frequency based on clinical trials and regulatory reporting:

Classification Examples of Documented Side Effects
Common (ge 1/100) Upper respiratory infection, headache, abdominal pain, diarrhea, nausea, fever.
Uncommon (ge 1/1,000) Dizziness, drowsiness, dry mouth, dyspepsia, rash, insomnia, anxiety, depression.
Rare (ge 1/10,000) Increased bleeding tendency, tremor, memory impairment.
Very Rare (< 1/10,000) Suicidal thinking and behavior, hallucinations, hepatitis, Churg-Strauss Syndrome.

Safety Restrictions and Considerations

  • Contraindication: Kastair is contraindicated in patients with known hypersensitivity to the drug's components.
  • Acute Attacks: It must not be used to treat sudden, acute asthma attacks. Appropriate rescue medication should be kept available.
  • Corticosteroids: Kastair should not be abruptly substituted for inhaled or oral corticosteroids.
  • Population-Specific: The chewable tablets contain phenylalanine, which is relevant for patients with Phenylketonuria (PKU). Use in pregnancy and lactation is limited to when it is considered clearly essential.

Overdose and Emergency Response

Overdose and When to Seek Help

Kastair (montelukast) has an established safety profile; however, specific measures are necessary in the event of an overdose. Overdoses have been reported in both adults and children, involving high single exposures up to 1000 mg of montelukast. In the majority of reported cases, individuals experienced no adverse effects.

Documented Overdose Symptoms

When symptoms did occur, the most frequent presentations observed were:

System Affected Common Symptoms
Gastrointestinal Abdominal pain, vomiting
Central Nervous System Headache, psychomotor hyperactivity, somnolence (drowsiness)
Other Thirst, and less frequently, convulsion

Emergency Response and Medical Attention

Immediate medical attention is required in any suspected overdose situation. Patients and caregivers should contact a Poison Help line or emergency medical services right away. Do not wait for symptoms to worsen.

Management for an overdose is supportive and symptomatic, focusing on general medical care and removing any unabsorbed material from the gastrointestinal tract. Regulatory sources indicate there is no specific antidote for montelukast overdose, and there is no adequate evidence to support the use of dialysis as an effective treatment method.

Therapeutic Uses of Kastair

What Kastair Treats: Main Uses and Benefits

Kastair is intended to address symptoms associated with specific chronic inflammatory conditions. It may be used to help reduce the intensity of acute symptoms, such as significant discomfort and joint stiffness, which may impact a patient's daily routine. The medication is associated with beneficial effects across chronic aspects of the condition and is an option for patients seeking symptom management.

Kastair may contribute to improving a patient's functional capacity, supporting movement and physical activities. This approach may support a higher quality of life by addressing persistent symptoms and promoting better daily function.

Quick Fact: Relief for Joint Discomfort

Eligibility and Restrictions for Use

Official Eligibility and Non-Eligibility for Kastair

Kastair (Montelukast) eligibility is strictly defined by regulatory guidelines concerning age, existing conditions, and physiological states. This information should be reviewed with a healthcare provider.

Classification Rule Restriction Context
Contraindicated Patients with known hypersensitivity to the drug or its components. Absolute exclusion.
Use Not Indicated Patients with acute asthma attacks (not a rescue medicine). Must not be used for emergency treatment.

Age-Specific Eligibility is based on the condition being treated, as efficacy is not established in all populations. Generally, use is not established in infants under 6 months of age for any indication, and age minimums differ for asthma versus allergic rhinitis. For exercise-induced bronchoconstriction, the minimum approved age is typically 6 years.

Use in Specific Populations requires special consideration:

  • Pregnancy and Lactation: Use is typically reserved only when the benefit is clearly essential or outweighs the potential risk.
  • Organ Function: No dose adjustment is usually required for mild-to-moderate hepatic impairment or renal insufficiency. Data for use in severe hepatic impairment are generally unavailable.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Regulatory documentation confirms specific drug–drug and drug–substance interaction patterns for Montelukast sodium (Kastair). These interactions primarily involve pharmacokinetic changes that alter the systemic exposure of Montelukast.

Pharmacokinetic and Exposure Alteration

Co-administration with substances that induce hepatic drug-metabolizing enzymes (CYP3A4, 2C8, and 2C9), such as Rifampicin and Phenobarbital, may decrease the plasma concentration of Montelukast. Conversely, the co-administration of Gemfibrozil, an inhibitor of CYP2C8, formally increases the systemic exposure (AUC) of Montelukast by approximately 4.4-fold, as documented in clinical studies.

Non-Drug and Administration Considerations

The Montelukast oral granule formulation exhibits a non-drug interaction with food: a high-fat meal is documented to decrease the peak plasma concentration (Cmax) by 35% but does not affect the overall drug exposure (AUC). Furthermore, the chewable tablet formulation contains phenylalanine (from aspartame) and is officially restricted for patients diagnosed with phenylketonuria (PKU). No mandatory time-separation rules are documented for co-administration with other medicinal products.

Population-Specific Notes

Caution is advised when potent CYP inducers, such as Rifampicin or Phenobarbital, are co-administered to pediatric patients due to the potential for reduced drug exposure. Additionally, patients with known aspirin sensitivity must continue to avoid aspirin or Non-Steroidal Anti-Inflammatory Agents (NSAIDs).

Mechanism of Action

Targeted Receptor Modulation

Kastair's action begins with the precise engagement of a defined receptor system within the central nervous system. The compound acts as a modulator at this target, adjusting the receptor's responsiveness to endogenous chemical signals. This targeted molecular interaction is the primary step in the mechanistic cascade, regulating the activity of key biological targets associated with specific physiological responses.

Influencing Signal Transduction Pathways

Following initial receptor engagement, Kastair operates by influencing intracellular signal transduction pathways. These are the sequential communication processes that convert the external receptor signal into a cellular change. Kastair modifies the activity and alters the signaling dynamics within these specific pathways, which are critical in systems requiring targeted cellular adjustment.

Systemic Adjustment of Physiological Responses

Functionally, the consequence of this mechanism is the modulation of activity within the defined receptor-mediated pathways. By influencing these core intracellular processes, Kastair results in an adjustment of receptor-linked activity, which subsequently leads to a measurable change in downstream molecular and physiological function across the affected systems.

Dosage and Administration Information

How to Use Kastair

Kastair (montelukast sodium) is administered solely through the oral route as part of a long-term, continuous treatment plan. The medication is available in several forms, including film-coated tablets, chewable tablets, and oral granules, with the specific strength determined by the patient's age.


Official Dosing and Frequency

Administration follows a once-daily schedule, which is essential for maintaining sustained management. For most chronic conditions, the dose is typically taken in the evening.

Age Group Standard Once-Daily Dose Forms Typically Used
Adults and Adolescents (ge 15 years) 10 mg Film-Coated Tablet
Children (6 to 14 years) 5 mg Chewable Tablet
Children (6 months to 5 years) 4 mg Chewable Tablet or Granules

The maximum recommended dose for adults and adolescents is 10 mg per day. For the prevention of exercise-induced bronchoconstriction, a single dose may be taken at least two hours before exercise, but patients should not take another dose within 24 hours.


Administration Requirements

Standard Tablets may be taken without regard to the timing of meals. Oral Granules must be administered immediately upon opening the packet (within 15 minutes) and can be mixed with a small amount of soft food (e.g., applesauce) or liquid; they must not be stored after mixing. Chewable Tablets require thorough chewing before swallowing.

Population-Specific Adjustments: There is no dosage adjustment necessary for older adult patients or those with renal impairment. If a dose is missed, patients should skip that dose and take the next scheduled dose at the regular time; taking two doses to compensate is not indicated.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Kastair

This section provides an overview of the types of clinical studies and scientific reports regulators rely on for Kastair (Montelukast sodium), detailing what was examined without offering interpretation, clinical advice, or treatment recommendations.

Evidence for Use in Chronic and Persistent Asthma

The evidence base for the medicine in this setting primarily relies on Randomized Controlled Trials (RCTs) and comprehensive Systematic Reviews. Research explored how symptoms change over time by monitoring objective outcomes like Forced Expiratory Volume in 1 second (FEV1), a common measure of lung function. Studies also examined patient-reported outcomes, such as asthma symptom scores and the utilization of rescue beta2-agonist use. Studies included populations where Kastair was administered as initial therapy and as an add-on treatment for participants also receiving inhaled corticosteroids. Some trials described patterns observed where the medicine was associated with measured changes in these outcomes when compared to placebo. However, research comparing Kastair directly to standard first-line inhaled treatments sometimes reported a smaller magnitude of measured change in lung function and symptom scores for Kastair. This research provides context but not individual predictions.

Evidence for Prevention of Exercise-Induced Bronchoconstriction

The research relevant in trials assessing short-term or episodic symptom patterns relies on Randomized, Double-Blind, Placebo-Controlled Crossover Trials. These studies focused on preventing outcomes describing episodic or acute changes that occur after physical activity. Researchers monitored the maximum percent fall in FEV1 following a controlled, standardized exercise challenge test. Findings describe patterns observed in the studies where the medicine was associated with a smaller measured drop in post-exercise FEV1 compared to placebo.

What is Still Uncertain in the Research Landscape

Research provides context but not individual predictions, and certain key limitations are noted across the evidence base. Inter-individual variability in patient response was observed in some studies, meaning research highlights what is known—and what is still uncertain—about which specific patient characteristics may or may not be associated with a more noticeable pattern of change. Comparative evidence against certain first-line therapies is sometimes lacking or reports that findings were mixed. Additionally, follow-up durations were limited in some pivotal trials, meaning long-term outcomes are not fully established for all populations or study types.

Frequently Asked Questions (FAQ)

Common questions about Kastair (FAQ)


Q: Are there common foods or drinks that should be avoided when taking Kastair?

Official guidelines state that Kastair tablets can generally be taken with or without food. However, the oral granule form must be administered immediately after opening and can only be mixed with specific soft foods, such as applesauce, or certain liquids. The mixed granules must not be stored for later use. No general avoidance of other common foods or drinks is mandated in the official prescribing information.


Q: How does Kastair interact with common pain relievers like ibuprofen?

Regulatory documents indicate that patients with known aspirin sensitivity must continue to avoid aspirin or Non-Steroidal Anti-Inflammatory Agents (NSAIDs), which include ibuprofen, while taking Kastair. For the general population, no warning is issued for the combination. This information indicates the importance of communication regarding all co-administered medicines.


Q: Can Kastair be taken with cold and flu medications?

Official regulatory documentation does not list cold and flu medications as a specific class that interacts with Kastair. The product label details interactions with specific medicines (like Gemfibrozil, Rifampicin, or Phenobarbital) that may alter the level of Montelukast in the body. Official information notes that reviewing the components of combination products for known interacting substances is consistent with label requirements.


Q: Can Kastair be crushed or chewed?

The official drug documentation specifies that the chewable tablets must be chewed thoroughly before swallowing. The standard film-coated tablets are administered orally, and official documentation does not specify instructions for crushing or altering this form.


Q: What happens in the body when Kastair is working?

Kastair is classified as a Leukotriene Receptor Antagonist (LTRA). This means it works by blocking the action of natural substances in the body called leukotrienes, specifically LTD4. Leukotrienes can cause swelling, tightening of airway muscles, and inflammation in the lungs. Blocking these inflammatory messengers helps to reduce these effects in the airways.


Q: Is Kastair available in a generic version?

Yes, the active ingredient in Kastair is montelukast sodium. This substance is available from several manufacturers as a generic medicine following its original approval by regulatory bodies like the FDA.


Q: What is the difference between Kastair and Singulair?

According to official documentation, Kastair and Singulair are two different brand names for the exact same active ingredient: Montelukast sodium. They are chemically the same compound.


Q: Is Kastair approved for use in young children?

Yes, Kastair is approved for use in young children, although the minimum age of approval depends on the condition being addressed. For example, for the treatment of perennial allergic rhinitis, use is established for children as young as 6 months of age based on official prescribing information.


Q: Why do official documents mention liver function when discussing Kastair?

Official regulatory documents mention liver function because Montelukast is primarily broken down, or metabolized, by specific enzymes in the liver (CYP3A4, 2C8, and 2C9). While no dosage adjustment is typically required for mild-to-moderate liver impairment, this biological process makes liver function a factor for regulators to document.


Q: Does Kastair have any known interactions with herbal supplements?

Official regulatory documents do not list specific interactions with common herbal supplements. Because these substances may not have been tested alongside Kastair in clinical studies, official information indicates that communication with a healthcare provider about all medicinal products, including herbal remedies, is consistent with product labeling.


Q: Is it necessary to avoid alcohol completely while on Kastair?

Official regulatory documentation does not contain a specific contraindication or mandatory avoidance warning for alcohol consumption. However, regulatory reports of liver injury have occurred in patients who had underlying liver disease, which can be related to alcohol use.


Q: Is Kastair available in different strengths?

Yes, Kastair is made available in different strengths and forms to suit various age groups and conditions, including 10 mg (film-coated tablet), 5 mg (chewable tablet), and 4 mg (chewable tablet and oral granules) forms.


Q: Does Kastair interact with birth control pills?

Official drug-drug interaction studies performed for Montelukast did not report any clinically significant interaction with oral contraceptives. No warning or mandatory time separation for administration is mentioned in the regulatory documentation.


Q: What should be done if someone experiences a serious side effect from Kastair?

Official regulatory safety communications describe an instruction to discontinue the medicine and contact a healthcare provider immediately if changes in behavior, new neuropsychiatric symptoms, or suicidal thoughts/actions occur.


Q: How is Kastair generally described regarding its safety profile?

The official safety profile for Kastair includes a Boxed Warning from the FDA, which is the agency’s strongest safety warning. This warning highlights the risk of serious neuropsychiatric events (changes in mood and behavior, including suicidal thoughts and actions) that have been reported in all age groups.


Q: Is Kastair suitable for people with pre-existing kidney issues?

Regulatory documentation states that no dosage adjustment is required for patients with renal insufficiency (kidney issues). This is because Montelukast is primarily processed and excreted through the bile, with a very small amount being recovered in the urine.


Q: Does Kastair require a special prescription in most regions?

Kastair is universally defined as a Prescription Drug (Rx) by regulatory bodies such as the FDA. Therefore, the requirement for a prescription from a licensed healthcare provider is standard across most regions.

How should Kastair be stored and disposed of?

Kastair (montelukast sodium) must be stored strictly according to regulatory guidelines to ensure product stability.


Required Storage Conditions

The medicine requires storage at Controlled Room Temperature, defined as 20 C to 25 C (68 F to 77 F). It is essential that the product be protected from both light and moisture and remain in the original container or original package.


Stability and Disposal Rules

For oral granules, the dose must be administered within 15 minutes of mixing with food or liquid, and the mixed product must not be stored for future use. The medicine must always be kept out of the sight and reach of children. Unused or expired Kastair must be disposed of according to local regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Kastair found in:

A-Z Index: